Enabling the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants including KP.2. (PubMed, Hlife) - Oct 24, 2026 - "Additionally, identical mutations in the complementarity determining regions (CDR)1 and CDR2 of the CB6 mutants also restored neutralizing potency for some RBD-1 group antibodies. Overall, the enhanced CB6 neutralizing capacity makes it a promising candidate against SARS-CoV-2 infection, and the BAADesign method has implications for the design of other antibodies."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CDR2
|
|
Chao Su; George Fu Gao; Jianxun Qi; Jing Zhang; Juanhua He; Ke Xu; Liang Wang; Longxing Cao; Mengsu Yang; Min Huang; Peipei Liu; Pengcheng Han; Qihui Wang; Rong Zhang; Shitong Qiao; Wenqiao Sun; Xin Li; Xin Zhao; Yu Hu; Yufeng Xie; Zhen Chang
|